Abstract
This study aimed to characterize the pharmacokinetics of tobramycin administered one, two, or three times daily and to develop an optimal dosing scheme for children with cystic fibrosis. Therapeutic drug monitoring data were obtained from children hospitalized at three academic medical centres from 2006 to 2012. Population pharmacokinetic models were constructed using NONMEM 7.2. Model-based simulations were performed in Matlab R2012b to identify optimal dosing regimens using pharmacodynamic targets. The pharmacokinetic analysis involved 257 patients with a median age of 8.1 years (range 0.1–18.8). Clearance was estimated as 5.59 L/h and the volume of distribution was 18.90 L. Mean (±SD) maximum serum concentrations were highest among patients dosed once per day (24.1 ± 8.9 μg/mL) and were lower among patients dosed two and three times per day (11.2 ± 1.4 and 8.1 ± 2.4 μg/mL, respectively). Simulations revealed that once daily dosing was the only effective regimen for a Pseudomonas aeruginosa MIC of 1.5 μg/mL and none of the tested regimens reliably achieved the pharmacodynamic target for MICs ≥2 μg/mL. Once daily dosing resulted in higher maximum serum concentrations when compared to multiple-daily dosing. In simulations, once daily dosing was the only regimen to achieve the pharmacodynamic target for all subjects with MICs <2 μg/mL.
Similar content being viewed by others
References
O’Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373(9678):1891–1904. doi:10.1016/S0140-6736(09)60327-5
Oppenheimer EH, Esterly JR (1975) Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 2:241–278
Zuckerman JB, Kotloff RM (1998) Lung transplantation for cystic fibrosis. Clin Chest Med 19(3):535–554
Cystic Fibrosis Foundation (2007) Cystic Fibrosis Foundation patient registry: 2006 annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda
Flume PA (2009) Pulmonary complications of cystic fibrosis. Respir Care 54(5):618–627
Ramsey BW (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335(3):179–188. doi:10.1056/NEJM199607183350307
Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG (2013) Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol. doi:10.1002/ppul.22813
Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J (2007) Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis—caution with trough concentrations. J Cyst Fibros 6(2):125–130. doi:10.1016/j.jcf.2006.05.015
Begg EJ, Barclay ML, Kirkpatrick CJ (1999) The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 47(1):23–30
Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ (2005) Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 39(1):15–20. doi:10.1002/ppul.20138
Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA (1988) Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 158(1):7–12
Vogelman BS, Craig WA (1985) Postantibiotic effects. J Antimicrob Chemother 15(Suppl A):37–46
Chambers HF (2010) Chemotherapy of microbial diseases: aminoglycosides. In: Brunton LL, Chabner BA, Knollman BC (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 12th edn. The McGraw-Hill Companies Inc, New York
Barza M, Ioannidis JP, Cappelleri JC, Lau J (1996) Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312(7027):338–345
Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A (2005) Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial. Lancet 365(9459):573–578. doi:10.1016/S0140-6736(05)17906-9
Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180(9):802–808. doi:10.1164/rccm.200812-1845PP
Smyth AR, Bhatt J (2012) Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2:CD002009. doi: 10.1002/14651858.CD002009.pub4
Young DC, Zobell JT, Stockmann C et al (2013) Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol 48(11):1047–1061
Jolley ME, Stroupe SD, Wang CH, Panas HN, Keegan CL, Schmidt RL, Schwenzer KS (1981) Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem 27(7):1190–1197
Ette EI, Williams PJ (2004) Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 38(10):1702–1706. doi:10.1345/aph.1D374
Ludden TM, Beal SL, Sheiner LB (1994) Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22(5):431–445
Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37(6):486–495
Burgess DS (2005) Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 40(Suppl 2):S99–S104. doi:10.1086/426189
Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R (1998) The pharmacodynamics of aminoglycosides. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 27(1):23–27
Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155(1):93–99
Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158(4):831–847
Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43(3):623–629
Mouton JW, Jacobs N, Tiddens H, Horrevorts AM (2005) Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 52(2):123–127. doi:10.1016/j.diagmicrobio.2005.02.011
Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T (2006) Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 58(4):822–829. doi:10.1093/jac/dkl328
Guglielmo BJ, Quan LA, Stulbarg MS (1996) Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. J Antimicrob Chemother 37(5):1040–1042
Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, Sardet A, Deschildre A, Druon D, Arrouet-Lagande C (1998) Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 78(6):536–539
Touw DJ, Knox AJ, Smyth A (2007) Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 6(5):327–333. doi:10.1016/j.jcf.2006.12.007
Cooney GF, Lum BL, Tomaselli M, Fiel SB (1994) Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 34(3):255–259
Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B (1984) Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 105(1):117–124
Town DJ, Vinks AA, Jacobs F, Heijerman HG, Bakker W (1996) Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther Drug Monit 18(5):562–569
Turnidge J (2003) Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am 17(3):503–528
den Hollander JG, Fuursted K, Verbrugh HA, Mouton JW (1998) Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 42(4):749–754
Craig WA, Redington J, Ebert SC (1991) Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27(Suppl C):29–40
Acknowledgments
The authors would like to thank Stephen B. Duffull, M Pharm (Clin), Ph.D, MPS University of Otago, New Zealand and Barbara Chatfield, M.D. Intermountain Cystic Fibrosis Paediatric Centre, UT, USA for their contributions to this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sherwin, C.M.T., Zobell, J.T., Stockmann, C. et al. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. J Pharmacokinet Pharmacodyn 41, 71–79 (2014). https://doi.org/10.1007/s10928-013-9348-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-013-9348-7